Detailed Information
Cited 52 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
KEYNOTE-522: Phase III study of pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) plus chemo as neoadjuvant treatment, followed by pembro vs pbo as adjuvant treatment for early triple-negative breast cancer (TNBC)
- Authors
- Schmid, P[Schmid, P.]; Cortes, J[Cortes, J.]; Dent, R[Dent, R.]; Pusztai, L[Pusztai, L.]; McArthur, HL[McArthur, H. L.]; Kuemmel, S[Kuemmel, S.]; Bergh, J[Bergh, J.]; Denkert, C[Denkert, C.]; Park, YH[Park, Y. H.]; Hui, R[Hui, R.]; Harbeck, N[Harbeck, N.]; Takahashi, M[Takahashi, M.]; Foukakis, T[Foukakis, T.]; Fasching, PA[Fasching, P. A.]; Cardoso, F[Cardoso, F.]; Jia, L[Jia, L.]; Karantza, V[Karantza, V.]; Zhao, J[Zhao, J.]; Aktan, G[Aktan, G.]; O'Shaughnessy, J[O'Shaughnessy, J.]
- Issue Date
- Oct-2019
- Publisher
- OXFORD UNIV PRESS
- Citation
- ANNALS OF ONCOLOGY, v.30, pp.853 - 854
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 30
- Start Page
- 853
- End Page
- 854
- ISSN
- 0923-7534
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.